What are the risks of using topiramate during pregnancy?

Topiramate is Contraindicated in Pregnancy Due to Significant Teratogenic Risk

Topiramate carries a substantially increased risk of oral clefts (cleft lip with or without cleft palate) when used during the first trimester of pregnancy, with an odds ratio of 6.26 (95% CI 3.13-12.51) compared to unexposed pregnancies 1, 2. This represents a 6-fold increased risk that is clinically significant and warrants absolute avoidance during pregnancy.

Primary Teratogenic Risk: Oral Clefts

The most well-established and concerning risk is orofacial clefting, particularly when exposure occurs during the first trimester:

• Meta-analysis data demonstrates an odds ratio of 6.26 for oral clefts with first-trimester topiramate exposure across 3,420 patients and over 1.2 million controls 1, 2
• This risk applies regardless of indication (epilepsy, migraine, weight loss, psychiatric disorders) 1
• Dose-dependent relationship: Higher doses carry greater risk, with doses >100 mg showing an odds ratio of 5.16 (95% CI 1.94-13.73) versus 1.64 for doses ≤100 mg 3
• Risk is more pronounced in women with epilepsy who typically use higher doses (median 200 mg vs 100 mg for other indications) 3

Additional Fetal Risks

Beyond oral clefts, topiramate demonstrates broader teratogenic potential:

• Hypospadias in male infants has been reported in post-marketing surveillance, though causality is not definitively established 4
• Animal studies show craniofacial defects, limb malformations (ectrodactyly, micromelia, amelia), and embryotoxicity at doses equivalent to or lower than human therapeutic doses 4
• Emerging evidence suggests neurodevelopmental risks including autism spectrum disorders, intellectual disability, and ADHD, though the magnitude appears similar to lamotrigine and lower than valproate 5

Regulatory Status and Prescribing Requirements

The FDA classifies topiramate as Pregnancy Category C (historically) and requires a Risk Evaluation and Mitigation Strategy (REMS) program 6, 4:

• Mandatory pregnancy testing before initiation and monthly thereafter 1, 6
• Effective contraception required for all women of reproductive potential 1, 6
• Immediate discontinuation if pregnancy occurs 1
• Certified pharmacies must participate in the REMS program to dispense phentermine/topiramate combinations 6

Clinical Management Algorithm

Preconception Planning:

1. Discontinue topiramate at least 1-2 months before attempting conception to allow complete drug clearance
2. Transition to safer alternatives (lamotrigine for epilepsy, other options for migraine/weight management)
3. Ensure adequate folic acid supplementation (higher doses may be warranted given teratogenic risk)

If Pregnancy Discovered While on Topiramate:

1. Stop topiramate immediately upon positive pregnancy test 1
2. Do not taper abruptly if used for epilepsy—coordinate rapid transition with neurology
3. Refer for high-risk obstetric care and detailed fetal anatomic ultrasound at 18-20 weeks focusing on orofacial structures
4. Consider fetal echocardiography given potential cardiac risks 7
5. Counsel about increased surveillance needs throughout pregnancy

Women of Childbearing Potential:

• Avoid topiramate as first-line therapy whenever possible 8
• If topiramate is essential (refractory epilepsy), use the lowest effective dose (<100 mg daily if feasible) 3
• Document contraception method and pregnancy testing compliance at each visit
• Consider alternative agents: levetiracetam shows superior effectiveness and safety profile in women with idiopathic generalized epilepsy 8

Important Caveats

The risk-benefit calculation heavily favors avoidance: Recent data show topiramate has lower effectiveness compared to levetiracetam in women of childbearing potential with idiopathic generalized epilepsy, with higher rates of treatment failure and withdrawal 8. This undermines any argument for accepting teratogenic risk based on superior efficacy.

Breastfeeding: Topiramate is excreted in breast milk and should be avoided during lactation due to unknown risks to the infant 2, 4.

Regulatory trend: Multiple agencies (RCOG, AACE, FDA) have progressively restricted topiramate use in women of reproductive potential, with recent guidance strongly discouraging its prescription in this population 2, 6.

The evidence is clear and consistent across multiple high-quality guidelines and research studies: topiramate poses unacceptable teratogenic risks during pregnancy and should be avoided in all women of childbearing potential unless no safer alternatives exist, and then only with rigorous pregnancy prevention measures.